Oramed Pharmaceuticals announced it will be added to the U.S. Russell 2000 and Russell 3000 indexes following the 2026 semi-annual reconstitution, effective June 29. This inclusion reflects Oramed's market capitalization ranking among the 4,000 largest U.S. stocks as of April 30, 2026. Being part of these indexes increases Oramed's visibility to investors and may attract more institutional investment. The Russell indexes are widely used benchmarks for investment funds, representing about $12.2 trillion in assets.
CEA Industries and YZi Labs have reached a cooperation agreement to strengthen governance at CEA Industries, which manages the world's largest corporate treasury of BNB. The agreement includes appointing three new board members with digital asset exp...
Axon Enterprise has been upgraded to a buy rating due to strengthened fundamentals and growth prospects, while its valuation remains stable. The company benefits from AI-driven full-stack solutions and strong international adoption, with over 100% ye...
uniQure Inc. has priced an upsized public offering of 4,945,055 ordinary shares at $45.50 each, aiming to raise approximately $225 million before expenses. The funds will support the company's development of transformative gene therapies for severe d...
The TBG Dividend Focus ETF maintains a 'hold' rating due to its competitive fundamentals within its category. It offers a robust 12.75% projected EPS growth for next year and an estimated dividend yield of 3.59%, which surpasses its trailing yield of...
Bitcoin has been trading below $70,000 for about three weeks, with recent whale purchases totaling over $43 million failing to push the price above $65,000. Large investors, or whales, have dominated market activity since early June, but their buying...
